Zinc Supplementation and Inflammation in Older Medical Patients
ZOOM-IN
ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial
1 other identifier
interventional
220
0 countries
N/A
Brief Summary
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years. The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2026
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 28, 2026
CompletedStudy Start
First participant enrolled
June 2, 2026
CompletedFirst Posted
Study publicly available on registry
June 26, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2028
June 26, 2026
June 1, 2026
12 months
May 28, 2026
June 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
inflammation 6 months
To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg/ml) from baseline to 6 months
6 months
Secondary Outcomes (11)
Blood samples indicating metabolic status and risk factors
3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
3 month, 6 month, 12 month
Patient reported Outcomes
3,6, and 12 months
- +6 more secondary outcomes
Study Arms (2)
Controlgroup
NO INTERVENTIONStandard treatment
Intervention
ACTIVE COMPARATOR22 mg zinc supplementation daily for 12 months
Interventions
Eligibility Criteria
You may qualify if:
- above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)
- admittet at the medical emergency department Herlev Hospital
You may not qualify if:
- Patients with terminal illness (life expectancy \< 6 months, estimated by Clinical Frailty Scale ≥8)
- Patients receiving parenteral nutrition (partial or complete)
- Patients treated with hemodialysis or peritoneal dialysis
- Patients known with severe dementia
- Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Herlev Hospitallead
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
May 28, 2026
First Posted
June 26, 2026
Study Start
June 2, 2026
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
May 31, 2028
Last Updated
June 26, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share